Patients receiving continuous bevacizumab accrued higher total costs ( +@ ( $ @ ) ; @ % CI @ to @ ; p = @ ) than those receiving discontinuous bevacizumab , but also accrued non-significantly more QALYs ( +@ ; @ % CI -@ to @ ; p = @ ) .